Ultragenyx Pharmaceutical to Sell FDA Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash. The voucher, awarded by the FDA in September 2026, is tied to the approval of FAYUVI (UX111) for MPS IIIA. The transaction, subject to closing conditions, aims to monetize the voucher and support strategic priorities.
How this was made
The 30-second read
Why it matters
The voucher sale provides a substantial non‑dilutive capital source, likely improving the company's balance sheet and funding flexibility.
Market read
A rare‑disease biotech company raises over $200 M through a voucher sale, a material corporate event that can move its stock.
What to watch
Potential tax implications of the cash receipt and the undisclosed buyer's identity could affect valuation.
Background
Ultragenyx received a Rare Pediatric Disease priority review voucher after FDA approval of its therapy FAYUVI (UX111) for MPS IIIA.
Ticker impact
Ultragenyx Pharmaceutical disclosed a $203 million sale of its FDA priority review voucher, a fresh primary filing that adds cash to the balance sheet.
likely upward pressure as investors price in the $203 M cash inflow
Voucher sales are rare and sizable; the market typically rewards the issuer with a share price bump.
Market effects
May signal increased activity in the rare‑disease biotech sector as companies consider monetizing PRVs.
Limited to U.S. biotech investors; no broader regional effect.
Low; the transaction is company‑specific.
Counterpoint
Some investors may view the voucher sale as a sign that the company lacks near‑term pipeline catalysts.
Key entities
- CompanyUltragenyx Pharmaceutical Inc.
Biotech firm developing treatments for rare diseases.
